Prediction of high-performing spleen-targeted lipid nanoparticles using a deep learning model for robust anticancer immunotherapy

T cell response in the spleen, outperforming clinically approved SM-102 and Dlin-MC3-DMA. Additionally, we demonstrated that YK-407 LNPs exhibited minimal toxicity for both the liver and spleen, with no significant inflammatory cytokine release. These findings highlight the potential of AI in LNP development and YK-407 holds great promise for applications in mRNA-based treatments.